The lawsuit centers on claims that Novo Nordisk misled investors about the tolerability and trial design of CagriSema, an experimental obesity treatment. Investors expected average weight loss results of around 25% but were disappointed when the actual results showed only 20.4%.
The court found that allegations regarding the trial's flexible dosing approach and its implications for drug tolerability were sufficient to move forward, although many other claims were dismissed. This ruling is significant as it allows investors to seek evidence supporting their claims, potentially affecting Novo's stock and investor confidence.
The company is currently facing increased competition from Eli Lilly's obesity drugs, making the success of CagriSema critical for its future. Novo has denied any wrongdoing and plans to defend itself vigorously as the case moves into the discovery phase